Exploration and Characterization Ofintratumoral Electrophysiological Heterogeneity in Gliomas Using Magnetoencephalography (GLIOMEG)
With more than 3,000 new cases per year in France, malignant gliomas are the most common malignant brain tumors in adults.
Treatment consists of surgical removal when possible. If this is not possible, a biopsy is performed to obtain a definitive anatomical and molecular diagnosis. Standard medical management after removal or biopsy is based on radio-chemotherapy. Despite this multimodal treatment, progression is the norm due to the invasive nature of these tumors. The prognosis remains very poor, with a median overall survival of around 18 months for glioblastomas.
Recent preliminary data indicate that magnetoencephalography (MEG) recordings can identify functional heterogeneity within a glioma. Functional analysis of these two types of areas has shown that the expression of synaptogenic factors is increased in areas of high functional connectivity compared to areas of low functional connectivity. Areas of high functional connectivity are more aggressive and more resistant to treatment.
In general, gliomas are characterized by a high degree of inter- and intra-tumoral heterogeneity. The latter has been well characterized at the transcriptomic level, and several distinct cell subpopulations have been described (classical, mesenchymal, proneural) This intra-tumoral heterogeneity is one of the factors contributing to resistance to current therapies, but it remains incompletely understood and explored. MEG is a tool capable of exploring intra- and inter-tumor heterogeneity from an electrophysiological perspective. This represents an original approach that will provide a better understanding of intra-tumor heterogeneity and lead to new therapeutic perspectives.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Julien BERTHILLER
- Telefonnummer: 04 27 85 63 01
- E-mail: julien.berthiller@chu-lyon.fr
Undersøgelse Kontakt Backup
- Navn: Thiébaud PICART
- Telefonnummer: 04 72 38 49 76
- E-mail: thiebaud.picart@chu-lyon.fr
Studiesteder
-
-
-
Bron, Frankrig, 69800
- Hospices Civils de Lyon
-
Kontakt:
- Thiébaud PICART, MCU PH
- Telefonnummer: 04 72 38 49 76
- E-mail: thiebaud.picart@chu-lyon.fr
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Male or female aged over 18
- With a newly diagnosed malignant glioma based on brain imaging
- Eligible for surgical removal
- Having given their consent
Exclusion Criteria:
- Contraindications to Magnetic resonance imaging (MRI) (claustrophobia, metallic implants, particularly intraocular implants, pacemakers)
- Contraindications to magnetoencephalography (MEG) (metallic implants in the mouth-dentures, fillings, crowns)
- Coagulation disorders
- Pregnancy, breastfeeding, or patients not using effective contraception
- Subjects participating in another interventional study with an exclusion period still in progress at the time of pre-inclusion, etc.
- Subjects deprived of their liberty by judicial or administrative decision
- Subjects receiving psychiatric care
- Subjects admitted to a health or social care facility for purposes other than research
- Adult subjects subject to legal protection measures (guardianship, curatorship)
- Subjects not affiliated with a social security system or beneficiaries of a similar system
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Diagnostisk
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: magnetoencephalography (MEG)
Every patients eligible for a glioma resection surgery
|
Eligible patients will undergo a complete Magnetoencephalography, of approximatively 45min
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Assess the technical feasibility of studying tumor electrophysiological heterogeneity using magnetoencephalography (MEG) in a series of patients with glioma at the initial stage of treatment.
Tidsramme: At baseline and during the 10 days prior to the date of surgery, according to the standard of care.
|
Percentage of patients with a complete and usable magnetoencephalography (MEG) recording, allowing intra- and peri-tumoral electrophysiological data to be collected and resting functional connectivity to be studied for all areas of the brain.
|
At baseline and during the 10 days prior to the date of surgery, according to the standard of care.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Define the radiological characteristics of the different types of areas of interest identified by MEG by comparing MEG mapping and preoperative MRI (anatomical and functional).
Tidsramme: At baseline and during the 10 days prior to the date of surgery, according to the standard of care.
|
Radiological patterns of areas identified by MEG, based on preoperative brain Magnetic resonance imaging (MRI) (morphological and functional)
|
At baseline and during the 10 days prior to the date of surgery, according to the standard of care.
|
|
Define the prognostic impact of ablation of areas with different electrophysiological properties, using an analysis that integrates MEG mapping data, post-operative MRI data, and survival data.
Tidsramme: At baseline and during the 10 days prior to the date of surgery, according to the standard of care.
|
Survival of patients with residual High Frequency Channel/ Low Frequency Channel (HFC/LFC) areas on postoperative MRI and survival of patients without such areas.
|
At baseline and during the 10 days prior to the date of surgery, according to the standard of care.
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 69HCL26_0020
- 2026-A01156-45 (Anden identifikator: ID-RCB)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med MEG
-
Hospices Civils de LyonMAG4HealthIkke rekrutterer endnu
-
National Institute of Mental Health (NIMH)RekrutteringNormal fysiologiForenede Stater
-
National Institute of Neurological Disorders and...Rekruttering
-
University of ArkansasAfsluttetPædiatrisk sprog- og hukommelseskortlægning ved refraktær epilepsi ved hjælp af magnetoencefalografiEpilepsiForenede Stater
-
Hospices Civils de LyonRekrutteringEpilepsi | Lægemiddelresistent epilepsi | Kandidater til kirurgisk behandlingFrankrig
-
Hospices Civils de LyonIkke rekrutterer endnuNormalt emne | Patient med farmako-resistent epilepsiFrankrig
-
Shalvata Mental Health CenterBar-Ilan University, IsraelUkendtSkizofrene patienterIsrael
-
University Hospital, GrenobleAfsluttetCerebral Primitiv Tumor Med Kirurgisk IndikationFrankrig
-
Hospices Civils de LyonAfsluttet
-
Institut PasteurInstitut de l'AuditionIkke rekrutterer endnu